 | Up a level |
Journal Article
Wendtner, Clemens, Hillmen, Peter, Mahadevan, Daruka, Stilgenbauer, Stephan, Uharek, Lutz, Coutre, Steven, Frankfurt, Olga, Bloor, Adrian, Bosch, Francesc 
ORCID: 0000-0001-9241-2886, Furman, Richard R., Kimby, Eva, Gribben, John G., Gobbi, Marco, Dreisbach, Luke, Hurd, David Duane, Sekeres, Mikkael A., Ferrajoli, Alessandra, Shah, Sheetal, Zhang, Jennie, de Parseval, Laure Moutouh and Chanan-Khan, Asher A.
(2010).
Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study).
Blood, 116 (21).
S. 591 - 593.
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 0006-4971
Wendtner, Clemens M., Hallek, Michael, Fraser, Graeme A. M., Michallet, Anne-Sophie, Hillmen, Peter, Durig, Jan, Kalaycio, Matt, Gribben, John G., Stilgenbauer, Stephan, Buhler, Andreas, Kipps, Thomas J., Purse, Brendan, Zhang, Jennie, De Bedout, Sabine, Mei, Jay and Chanan-Khan, Asher (2016). Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. Leuk. Lymphoma, 57 (6). S. 1291 - 1300. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403